Kiora Pharmaceuticals Inc (KPRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Kiora Pharmaceuticals reported revenue of $0, down 100.0% from $16.0M the year before. Net income was -$10.8M, or -$2.64 per diluted share. Operating activities generated -$10.0M of cash, leaving -$10.1M of free cash flow. At fiscal year end, Kiora Pharmaceuticals held $24.3M in total assets against $8.1M in total liabilities, including $8.7M of cash and equivalents.
Open the full interactive Kiora Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Kiora Pharmaceuticals Key Stats
| Share Price | $2.47 |
|---|---|
| Market Cap | $15.3M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $1.80 – $2.86 |
| Shares Outstanding | 6.2 million (basic, 2026 Q2) |
Kiora Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $12,059 | $0 | $0 | $0 | $16.0M | $0 |
| Operating Income | — | -$16.9M | -$12.3M | -$12.6M | $4.5M | -$12.8M |
| Pre-Tax Income | $8.1M | -$16.7M | -$13.7M | -$12.4M | $5.7M | -$12.1M |
| Income Tax | $12,055 | -$304,781 | -$113,010 | $90,319 | $2.1M | -$1.3M |
| Net Income | -$8.1M | -$16.4M | -$13.6M | -$12.5M | $3.6M | -$10.8M |
| Diluted EPS | -$637.20 | -$637.20 | -$166.95 | -$24.21 | $0.87 | -$2.64 |
Kiora Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | $26,806 | -$6.5M | -$2.4M | -$2.1M |
| Diluted EPS | $0.01 | -$1.59 | -$0.58 | -$0.34 |
Kiora Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.2M | $7.9M | $6.0M | $2.5M | $3.8M | $8.7M |
| Current Assets | $1.8M | $9.0M | $7.7M | $4.7M | $29.7M | $21.7M |
| Total Assets | $15.2M | $18.1M | $18.7M | $13.7M | $36.5M | $24.3M |
| Current Liabilities | $1.8M | $1.6M | $3.3M | $1.6M | $6.0M | $3.6M |
| Total Long-Term Debt | $278,190 | — | — | — | — | — |
| Total Liabilities | $8.2M | $8.8M | $7.3M | $7.6M | $10.7M | $8.1M |
| Shareholders' Equity | $7.0M | $9.2M | $11.4M | $6.1M | $25.8M | $16.1M |
Kiora Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$7.3M | -$10.9M | -$10.4M | -$9.6M | $8.6M | -$10.0M |
| Cash From Investing | -$244,438 | -$157,020 | $6,375 | $0 | -$22.7M | $14.4M |
| Cash From Financing | $5.0M | $17.8M | $8.6M | $6.0M | $15.5M | $265,655 |
| Free Cash Flow | -$7.3M | -$11.0M | -$10.4M | — | $8.6M | -$10.1M |
Figures from Kiora Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Kiora Pharmaceuticals financials page for every line item.
Kiora Pharmaceuticals Company Profile
| Ticker | KPRX |
|---|---|
| Exchange | Nasdaq, OTC |
| Industry | Pharmaceutical Preparations |
| Headquarters | Encinitas, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001372514 |
Frequently Asked Questions
What was Kiora Pharmaceuticals' revenue in fiscal 2025?
Kiora Pharmaceuticals (KPRX) reported revenue of $0 for fiscal 2025.
What is Kiora Pharmaceuticals' annual revenue history?
Kiora Pharmaceuticals' annual revenue by fiscal year: 2020: $12,059; 2021: $0; 2022: $0; 2023: $0; 2024: $16.0M; 2025: $0.
What was Kiora Pharmaceuticals' net income in fiscal 2025?
Kiora Pharmaceuticals reported net income of -$10.8M for fiscal 2025.
What was Kiora Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Kiora Pharmaceuticals' diluted EPS was -$2.64 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Kiora Pharmaceuticals generate in fiscal 2025?
Kiora Pharmaceuticals generated -$10.1M of free cash flow in fiscal 2025.
What was Kiora Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Kiora Pharmaceuticals reported revenue of $0.
How many shares of Kiora Pharmaceuticals are outstanding?
Kiora Pharmaceuticals reported a weighted average of 6.2 million basic shares outstanding in 2026 Q2.
What is Kiora Pharmaceuticals' market cap?
Based on its latest closing price, Kiora Pharmaceuticals (KPRX) has a market capitalization of about $15.3M.
When does Kiora Pharmaceuticals' fiscal year end?
Kiora Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Kiora Pharmaceuticals headquartered?
Kiora Pharmaceuticals lists its business address in Encinitas, California in its SEC filings.